A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors

Table 3 Immunohistochemistry analysis of whole tumor and IM of pretreatment tumor biopsies

Cancer Type	BOR	%PD-L1⁺	%CD8⁺ ALL^a	%FoxP3⁺ ALL^a	CD8/FoxP3 ALL^a	%CB8⁺ IM^b	%FoxP3⁺ IM^b	%CD137⁺ IM^b	CD8/FoxP3 IM^b
NSCLC	PR	0.00	1.70	1.72	0.99	9.96	1.45	14.21	6.87
SCCHN	PD	0.00	6.89	5.38	1.28	13.28	6.48	8.59	2.05
SCCHN	SD	0.00	17.16	1.74	9.86	NE	NE	NE	NE
SCCHN	SD	10.00	13.69	4.98	2.75	NE	NE	NE	NE
SCCHN	SD	0.00	12.23	9.43	1.3	14.68	10.05	10.37	1.46

Marker-positive cells are reported as a percent of evaluated cells
^aALL: The region encompassing the tumor and extending up to the leading edge, but not outside the tumor-normal interface
^bIM: The region extending from 500 μm outside the leading edge of the tumor to 500 μm inside
BOR Best overall response, NE Not evaluable, NSCLC Non–small-cell lung cancer, PD Progressive disease, PD-L1 Programmed cell death-ligand 1, PR Partial response, SCCHN Squamous cell cancer of head and neck, SD Stable disease